{"nctId":"NCT02727907","briefTitle":"Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis","startDateStruct":{"date":"2015-02-12","type":"ACTUAL"},"conditions":["Multiple Sclerosis"],"count":163,"armGroups":[{"label":"BCD-033","type":"EXPERIMENTAL","interventionNames":["Drug: BCD-033 (interferon beta 1a)"]},{"label":"Rebif","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Rebif (interferon beta 1a)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"BCD-033 (interferon beta 1a)","otherNames":[]},{"name":"Rebif (interferon beta 1a)","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Age 18-55\n2. Patients of both genders with Multiple Sclerosis (McDonald criteria 2010)\n3. No relapses 28 days before randomisation\n4. Expanded Disability Status Scale score 0-5,5\n\nExclusion Criteria\n\n1. Primary or secondary progression of Multiple Sclerosis\n2. Expanded Disability Status Scale score more then 5,5\n3. Severe depression, suicide ideas and/or attempts\n4. Systemic corticosteroid application in 30 days before randomisation","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"55 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Combined Unique Active Lesions","description":"Number of Combined Unique Active Lesions (CUA) -- the number of new MRI contrast uptake lesions on T1 images, and new or expanding lesions on T2 images (lesion identified on T1-and T2 images is not counted twice) after 52 weeks blinded application of interferon-β1а (BCD-033 and Rebif®) (44 mcg).","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Annual Relapse Rate","description":"Annual relapse rate ARR for 52 weeks was evaluated in all three groups, after the application of IFN beta-1a","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.113","spread":"0.375"},{"groupId":"OG001","value":"0.091","spread":"0.348"},{"groupId":"OG002","value":"0.109","spread":"0.369"}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects Without Confirmed Relapse","description":"proportion of subjects without confirmed relapse in PP","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"46","spread":null},{"groupId":"OG002","value":"45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"44","spread":null},{"groupId":"OG002","value":"39","spread":null}]}]}]},{"type":"SECONDARY","title":"Relapse Free Time","description":"Time to first relapse in \"per protocol\" population","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"207.0","spread":null},{"groupId":"OG001","value":"183.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Combined Unique Active Lesions","description":"CUA (the number of new contrast-enhanced lesions on T1 images, and new or expanding lesions on T2 images (lesion identified on T1-and T2 images is not counted twice)","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Annual Relapse Rate","description":"Annual Relapse Rate ARR for 96 weeks was evaluated in two groups, after the administraion of IFN beta-1a in a full dose for 96 weeks.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.208","spread":"0.532"},{"groupId":"OG001","value":"0.145","spread":"0.524"}]}]}]},{"type":"SECONDARY","title":"Relapse Free Time","description":"Time to first relapse in \"per protocol\" population","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.5","spread":null},{"groupId":"OG001","value":"14.0","spread":null},{"groupId":"OG002","value":"15.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"193.0","spread":null},{"groupId":"OG001","value":"123.5","spread":null},{"groupId":"OG002","value":"74.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Combined Unique Active Lesions","description":"CUA (the number of new contrast-enhanced lesions on T1 images, and new or expanding lesions on T2 images (lesion identified on T1-and T2 images is not counted twice).","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"1.0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Adverse Events/Serious Adverse Events","description":"quantity and grade of all AE/SAE is calculated in subjects, who received at least one dose of study drug","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"124","spread":null},{"groupId":"OG001","value":"110","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Severe Adverse Events Frequency","description":"AE grade 3-4 (CTCAE 4.03) is calculated in subjects, who received at least one dose of study drug","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Withdrawal","description":"quantity of withdrawals due to AE/SAE is calculated in subjects, who received at least one dose of study drug","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Immunogenicity","description":"Count of Participants with Binding and Neutralizing Antibodies","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Adverse Reaction/Serious Adverse Reactions","description":"quantity and grade of all adverse reactions/serious adverse reactions is calculated in subjects, who received at least one dose of study drug","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"59","spread":null},{"groupId":"OG002","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"80","spread":null},{"groupId":"OG002","value":"92","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Severe Adverse Events Frequency","description":"AE grade 3-4 (CTCAE 4.03)is calculated in subjects, who received at least one dose of study drug","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Withdrawal","description":"quantity of withdrawals due to AE/SAE is calculated in subjects, who received at least one dose of study drug","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Immunogenicity","description":"Count of Participants with Binding and Neutralizing Antibodies","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Serious Adverse Events","description":"quantity and grade of all SAE is calculated in subjects, who received at least one dose of study drug","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":53},"commonTop":["flu-like syndrom","local reaction","neutropenia","fever","lymphopenia"]}}}